Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Kyowa Kirin Co., Ltd. (4151:JPX), powered by AI.
Kyowa Kirin Co., Ltd. is currently trading at ¥2,388.5. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Kyowa Kirin Co., Ltd. on Alpha Lenz.
Kyowa Kirin Co., Ltd.'s P/E ratio is 18.6.
“Kyowa Kirin Co., Ltd. trades at a P/E of 18.6 (fair value) with modest ROE of 7.7%. Operating margin of 20.6% indicates strong profitability.”
Ask for details →Kyowa Kirin Co., Ltd. is a prominent pharmaceutical company based in Japan, specializing in the research, development, and marketing of pharmaceuticals, biotechnology products, and medical devices. Its primary function revolves around creating innovative solutions for unmet medical needs, with a specific focus on therapeutic areas such as oncology, nephrology, immunology, and the central nervous system. Kyowa Kirin's commitment to research and development is underscored by significant investments in cutting-edge biotechnology and partnerships that foster scientific advancements. The company's contribution extends to providing effective healthcare solutions globally, impacting various industries including healthcare, pharmaceuticals, and biotechnology. As a leading player in the pharmaceutical sector, Kyowa Kirin plays a crucial role in advancing medical science and improving patient outcomes through its diverse product offerings and ongoing clinical trials. This makes it an influential entity within Japan's pharmaceutical industry and the global market at large, continuing to drive innovation and therapeutic discoveries.
“Kyowa Kirin Co., Ltd. trades at a P/E of 18.6 (fair value) with modest ROE of 7.7%. Operating margin of 20.6% indicates strong profitability.”
Ask for details →Kyowa Kirin Co., Ltd. (ticker: 4151) is a company listed on JPX in the Healthcare sector (Drug Manufacturers - General). It has approximately 5,669 employees. Market cap is $1.3T.
The current price is 2,388.5 with a P/E ratio of 18.65x and P/B of 1.4x.
ROE is 7.69% and operating margin is 20.59%. Annual revenue is $496.8B.